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Biomaterials in RNAi therapeutics: quo vadis?
Ernst Wagner*
The fifteen years of utilizing RNAi present a surprise story, ranging from the unexpected discovery and
publication of RNA interference in 1998, rewarded by the nobel prize in 2006, the introduction of syn-
thetic short siRNAs for the specific gene silencing in mammalian cells in 2001, or the discovery of more
than 1600 human microRNAs naturally regulating about one third of our genes. Therapeutic applications
started amazingly fast and resulted in the first recent successes in therapy. Synthetic siRNAs are under
evaluation for knocking down disease-associated target mRNAs, microRNA mimics for turning on or
antagonists (antagomirs) for turning off microRNA activity. Modified oligonucleotides comprise a special
class of therapeutics with a new chemical profile; the precise synthetic molecules are much smaller than
protein or gene vector drugs, but they are larger than conventional drugs and thus cannot passively
diffuse into their target cells. The main current strategies for solving the delivery problem are discussed.
We now face the interesting question of alternative future directions: should oligonucleotide molecules
be chemically further minimized into small drug-like chemical entities? Or should multiple RNAi mole-
cules be wrapped up into larger virus-like nanoparticles for delivery? Biomaterials in therapeutic RNA
interference, quo vadis?
1. Introduction
The discovery of RNA interference (RNAi)1 has fundamentally
changed our knowledge in biology about gene regulation.
Small double-stranded RNA molecules, either derived from our
endogenous >1600 human microRNA genes2 or artificially
introduced from outside, are processed into a so-called RISC
complex, which have one (‘guide strand’) of the two 21–23
nucleotide long RNA strands incorporated in phosphorylated
form complexed with argonaute (Ago) protein.3 These RISC
complexes similarly as antisense oligonucleotides recognize in
the intracellular cytosol complementary target messenger RNA
(mRNA) and prevent protein translation. Natural human
microRNA RISCs4,5 contain predominantly argonaute Ago1 or
Ago2 and regulate about one third of our genes. The sequence
match with the target mRNA is only partial and is strictly
required for the first 7–8 nucleotides (seed region); these
microRNA RISCs interfere by hybridization and sterically
blocking mRNA against translation; subsequent mRNA degra-
dation occurs by other processes. In contrast, siRNA RISCs
containing Ago2 with an endonuclease domain can cleave per-
fectly matched complementary mRNA in a catalytic fashion.
In mammals this process is not naturally occurring, but can be
artificially triggered by the introduction of synthetic short
siRNA molecules.6
This enhanced understanding of gene regulation has
opened our mind for new medical concepts (Fig. 1).7–9 Novel
therapeutics based on synthetic siRNAs can be utilized to
silence malfunctioning or disease-promoting genes. Introduc-
tion of microRNA mimics of ‘tumor suppressor’ miRs for
turning on therapeutic microRNA activity displays encouraging
anticancer activity.10,11 Conversely, single-stranded oligo-
nucleotides complementary to microRNA RISCs may act as
antagonists (antagomirs)12 for turning off tumor-associated
‘onco’ microRNA activity. Altogether, RNAi therapeutic modu-
lators comprise a new class of medium-sized therapeutics
based on synthetic single- or double-stranded modified RNA
oligonucleotides. For broader medical translation, delivery to
their intracellular cytosolic site of drug action is the key
current limitation, as these molecules cannot passively diffuse
into their target cells.13 In the following, diverse strategies for
overcoming the roadblocks of delivery are reviewed.
2. Strategies to maximize cytosolic delivery
The main roadblocks against efficient cytosolic siRNA delivery
are as follows: (i) Double-stranded siRNA oligonucleotides are
too charged, too large and too rigid to migrate across cellular
membranes. (ii) They are however small enough to be rapidly
removed from blood circulation by renal clearance. (iii) They
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are biologically vulnerable and degraded in the extracellular
and intracellular biological environments. (iv) As negatively
charged oligonucleotides they may be recognized by Toll-like
receptors (TLRs) and may trigger innate immune reactions.
Each of these obstacles has already been separately solved;
combinations for overcoming all barriers are being developed.
Different approaches are being considered for the develop-
ment of siRNA and related RNAi modulating therapeutics:
chemical and covalent conjugate approaches, which tend to
produce small drug-like entities; encapsulation and complexa-
tion approaches, which favor nanoparticle formation. The
debate remains open whether RNAi compounds should be
designed to be as small molecules as possible, to be able to
diffuse to and into the target cell almost like a standard drug,
or whether siRNA molecules should be provided as cohorts of
multiple copies packaged into a larger nanoparticle.
2.1 The chemistry approach
A more than thirty years experience in antisense oligo-
nucleotide chemistry has been utilized to make RNAi oligo-
nucleotides metabolically much more stable and non-
immunogenic.14,15 For example (see Fig. 2), substituting the
natural ribonucleotides by 2′-O-methyl or 2′-F ribonucleotides
and introducing phosphorothioates into the oligonucleotide
backbones enhances stability and reduces TLR activation.
Chemistry also addresses the question: can RNAi oligos
be minimized into smaller more drug-like molecules? The
structural space for chemical modification however is limited
by special requirements in the RNA–RNA interactions with Ago
within the RISC. In this respect, chemically bridged ribo-
nucleotides with their conformation locked in A-form have
been assembled into locked nucleic acids (LNAs). Due to
strong RNA base pairing, LNAs are very effective as antagomirs;
even eight nucleotides short “tiny LNAs” which target the
seed-region are sufficient for microRNA inactivation.16
Shortening of oligonucleotides such as LNAs to 16 or less
nucleotides improves intracellular delivery.17 Endocytic pro-
cesses named ‘gymnosis’ result in therapeutically relevant
cytosolic levels without the help of additional carrier agents.
Tricyclo-DNA (tc-DNA) is another new class of RNA-binding oligo-
nucleotides with encouraging pharmacological properties.18
Structural requirements for agonistic siRNAs and micro-
RNAs are more demanding than those for antagonistic antogo-
mirs. For RISC incorporation, the double stranded siRNA has
to be delivered. The most recent breakthrough in the field has
been the development of potent single stranded siRNA.19,20
Two measures were required for this success: optimizing the
chemical stability of single stranded ss-siRNA by introducing
alternating 2′-F and 2′-OMe nucleosides in the strand, 2′-meth-
oxyethyl at the ends, and phosphorothioates in most positions.
Without these modifications single stranded RNA would be far
more vulnerable than double stranded siRNA. The second key
measure was the introduction of 5′-vinylphosphonate as meta-
bolically stable mimics of 5′-phosphorylated RNA required in
RISC formation. Importantly, stabilized ss-siRNA mediated
effective gene silencing also in vivo, illustrated by factor VII
and apoCIII mRNA knockdown in the liver upon intravenous
administration,19 or suppression of mutant huntingtin in
the CNS upon intracerebral spinal fluid administration in a
Huntington mouse model.20
Fig. 1 RNA interference modes of action. Incorporation of guide RNA strand
(derived from natural microRNA or introduced siRNA) together with argonaute
(Ago1 or Ago2) into the RNA interference silencing complex (RISC). RISCs recog-
nize complementary messenger RNA (mRNA) strands by hybridization, which
always matches in the seed region (the first 7–8 nucleotides of 5’-end of the
guide strand). In the case of a perfect sequence match over the whole guide
strand, Ago2 RISCs (which contain an endonucleolytic RNase activity) cleave the
target mRNA in a catalytic mode, whereas RISCs with the partial sequence
match repress protein translation by mRNA blockade. Green diamonds present
options for artificial induction of RNA interference (1: synthetic siRNA; 2: syn-
thetic pre-microRNA; 3: single stranded ss-siRNA), the red diamond presents
options for inhibition of RNA interference (4: antagomirs such as tiny-LNA,
masking the RISC guide strand by hybridization).
Fig. 2 Structures of oligonucleotide modifications. PS, stabilizing phos-
phorothioate linkages; 2’-OMe, 2’-O-methyl-RNA; 2’-F, 2’-fluoro-RNA; MOE,
2’-O-methoxyethoxy-RNA; LNA, locked nucleic acid nucleoside; tc-DNA, tricycle-
DNA nucleoside.
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2.2 The conjugate approach
Chemical stabilization and size minimization very favourably
improve the pharmacological properties of RNAi modulating
oligonucleotides, but do not solve the delivery problem com-
pletely. A more effective and ideally tissue-targeted intra-
cellular delivery is requested. Thus, targeting ligands21
such as galactoside derivatives,22 folic acid,23 cholesterol or
lipids19,24,25 have been conjugated with oligonucleotides or
siRNA (see Fig. 3A). Cholesterol-modification mediates lipopro-
tein binding in blood, thus preventing renal clearance, and
triggers cellular uptake by the LDL receptor. Ligand incorpor-
ation may support cell binding, possibly also the uptake by
endocytosis, however does not resolve the intracellular release
problem.
Different types of covalent conjugates of siRNA with cat-
ionic polymers have been synthesized, with the polycations
neutralizing the negative oligonucleotide charges and,
after cellular uptake by endocytosis, promoting escape from
endosomes into the cytosol.26,27 Such ‘dynamic polyconju-
gates’ (Fig. 3B) may incorporate several functions (targeting
ligands, surface shielding with poly(ethylene glycol) (PEG),
endosomolytic domains), however present structures signifi-
cantly larger than a single siRNA molecule. Smaller and mole-
cularly more precise cationic oligospermine siRNA conjugates
were prepared stepwise on an oligonucleotide synthesizer.
Such a cationization was sufficient for carrier-free siRNA trans-
fection in cell culture.28
2.3 The encapsulation approach
Different from the small molecule and conjugate approaches,
siRNA molecules can be encapsulated in multiple copies into
larger structures. Liposomal systems with bioreversible PEG
shielding and sizes of around 100 nm are very effective delivery
vehicles for various drugs including siRNA. For these purposes
SNALPs (stable nucleic acid lipid particles) were developed.29,30
The observed tropism resulting in high gene silencing activity
in liver hepatocytes is based on association with lipoprotein
apoE during blood circulation as a ligand for receptor-
mediated uptake.31 The fusogenicity of incorporated lipids
supports the cytosolic release of the multiple incorporated
siRNA molecules. It is not surprising that several encouraging
clinical therapeutic RNAi studies targeting the liver are based
on this robust platform.
2.4 The complexation approach
Negatively charged molecules such as oligonucleotides or
siRNA can be complexed with recombinant nucleic acid
binding proteins,13 peptides,32–34 cationic nature-derived poly-
mers like chitosan35 or synthetic polycations such as various
polyethylenimine derivatives36,37 into various nanoparticle
forms (‘polyplexes’).38,39 Interestingly, polyplex sizes and stabi-
lities are much more sensitive to the nature of the nucleic acid
payload40 as compared to liposomal formulation, where the
lipid bilayer but not the encapsulated material determines bio-
physical properties. This can be regarded as an advantage or
as a disadvantage. On the one hand, a polymer formulation
optimized for plasmid DNA (pDNA) may not at all be appli-
cable for siRNA. Thus, several strategies have converted small
siRNA into larger pDNA-like structures.41,42 On the other hand,
tuning of polymers for a given nucleic acid payload can
provide nanoparticles with diverse properties, for example
with polyplex sizes as small as 7 nm (for polymer-decorated
single siRNA molecules) or as large as a micrometer (for siRNA
aggregates). Polymers, in contrast to cationic lipids, usually are
molecularly less precise, polydisperse molecules. This draw-
back, however, can be overcome by recent chemical designs
such as solid-phase supported assembly of sequence-defined
polymers.43–45 Fig. 4 displays a sequence-defined ligand-PEG-
cationic oligomer used for functional monomeric siRNA poly-
plex formation.
Fig. 3 Covalent conjugates for RNAi delivery. (A) Monofunctional modifi-
cations include receptor targeting ligands such as N-acetyl-galactosamine
(NAG), or lipophilic modifications such as cholesterol. (B) An example of a multi-
functional dynamic polyconjugate.26 The amide bonds are cleaved at intracellu-
lar endosomal acidic pH, the disulfide bond between siRNA and carrier polymer
reduced by glutathione (GSH) within the cytoplasm.
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3. Design in RNAi therapeutics: quo vadis?
The different presented approaches (optimized oligonucleotide
chemistry; conjugates; liposomal formulation; polymer-based
nanoparticles) synergize in several aspects. Incorporation of
functional transport domains, such as shielding in the blood
circulation, cell targeting, or endosomal membrane pene-
tration and combinations, can be beneficial in most of the for-
mulation approaches as has already been demonstrated in
several cases.23,26,46 For example, receptor-targeted siRNA con-
jugates can benefit from complexation with endosomally active
polymers.23 Chemical oligonucleotide stabilization will be very
useful also for all delivery approaches.
In other aspects – especially in the size dimension – the
strategies go into completely different directions (Fig. 5A). Will
minimized small carrier-free oligonucleotide strands be
designed exerting still meaningful target sequence specificity?
Or will small targeted nanoparticles or larger micro–nano
composites be the preferred RNAi drug option?
The answer may depend on the medical indication, the
physiology of the affected biological tissue, and the kind of
(local, topical or systemic) administration. Furthermore, one
larger targeted polyplex, if successfully delivered into a cell,
may release an armada of hundreds of siRNA molecules into
the cytosol. For the same effect mediated by free or monomole-
cular complexed siRNA sneaking into the cell, hundreds of
successful events would be required. Thus, medium–large
nanoparticles and shielded liposomes might be interesting for
intravenous targeting of areas with enhanced vasculature per-
meability such as tumors or inflammation sites, where they
benefit from passive retention.47 In contrast, in tissues with
restricted drug diffusion, very small RNAi compounds might
be advantageous.
Future RNAi therapeutic formulations can be envisioned
which combine the best of all the mentioned diverging pro-
perties and act like shuttle-based systems (Fig. 5B): larger
shielded and targeted nanoparticles (based on lipids, polymers
or other controlled release scaffolds) deliver their payload to
the diseased region, where biologically triggered smaller drug-
loaded subunits are released which facilitate the intracellular
transport and subsequent time-controlled extended release of
the minimized RNAi drug.
Fig. 4 Complexation with polymers. An example of 6 nm small monomolecular
siRNA polyplexes formed with sequence-defined oligomers is presented.46
Oligomers contain a targeting ligand (folic acid), a poly(ethylene glycol) (PEG)
unit for particle surface shielding, an endosomal protonatable artificial amino
acid (Stp), and terminal cysteines for polyplex stabilization by disulfide
formation. The siRNA is covalently linked to an endosomolytic peptide.
Fig. 5 RNAi delivery strategies with diverse characteristics. (A) Different dimen-
sions of RNAi molecules and formulations. (B) Shuttle-type RNAi delivery systems
consisting of larger shielded and targeted nanoparticles which deliver their
payload to the diseased region, where the specific altered microenvironment is
supposed to trigger the release of smaller RNAi subunits.
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4. Conclusion and prospects
The recent knowledge about RNA interference has yielded
powerful tools for manipulating gene expression both for
pharmacological scientific and therapeutic purposes. The
typical active drug substances present synthetic double
stranded siRNAs of 21 base pairs for the sequence-specific rec-
ognition and cleavage of mRNA complementary to the siRNA
guide strand, but they can be as small as 8 nucleotide tiny
LNAs to act as antagomirs or as large as a viral gene vector
expressing an RNAi gene. Based on oligonucleotide structure,
the novel class of RNAi drugs resides between classical small
chemical drugs and macromolecular biological drugs (such as
proteins). Current developments have already proven that
RNAi drugs can be optimized into biologically stabilized drug-
like molecules, which can be synthesized with high precision
like conventional drugs. Despite the far more limited intra-
cellular bioavailability as compared with classical drugs,
potent RNA interference in vivo has been obtained in some
cases. It will be interesting to see whether further chemical
tuning of the oligonucleotide chemistry will open up the
pharmacological window for broader therapeutic use. Alterna-
tively or in combination, the RNAi drug substance can be
incorporated into controlled release formulations. Enhanced
delivery to the target tissue, better intracellular uptake, and
extended local release may favourably improve both the speci-
ficity and pharmacokinetics of the RNAi drug. Improved
macromolecular chemistry such as solid-phase-supported
syntheses, and innovative nanotechnology assembly methods
including microfluidic technologies are available for designing
more sophisticated multifunctional, but chemically still
precise carriers. It may depend on the route of administration
and the disease indication whether the road of optimization
will lead to drug-like single RNAi molecule conjugate ‘nano-
agents’ or towards larger delivery shuttles locally or intracellu-
larly releasing an armada of RNAi drug molecules.
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